Alzheimer's Disease Trial, Not Yet Recruiting NCT07485153 Sponsor: Eli Lilly and Company Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07485153
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have mild memory or thinking difficulties, self-reported memory concerns, or normal thinking and memory abilities.
  • People who have evidence of Alzheimer's-related changes in the brain, shown through a brain scan (PET scan) or through testing of fluid from the spine or blood.
  • People who score 24 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA).
  • People whose results on a standard scale used to measure dementia (the Clinical Dementia Rating Scale) show a global score of either 0 or 0.5.
  • People who are able to read, understand, and sign a consent form agreeing to take part.
  • People who have been on a stable set of medications (including any Alzheimer's medications) for at least 30 days before the study begins, and who are willing to keep taking the same medications throughout the study.
  • People who have a close friend or family member who knows them well and can attend certain study visits to answer questions about the participant.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a serious illness that the study doctor believes would make it difficult for them to take part safely.
  • People with a skin condition that may interfere with study assessments.
  • People who have a pacemaker or an implantable heart device called a cardioverter defibrillator.
  • People who have been diagnosed with a sleep disorder.
  • People who have irregular sleep patterns, such as those who regularly work night shifts.
  • People who are pregnant or currently breastfeeding at the time of their screening assessment.
  • People who use sleep aid medications (such as melatonin, Ambien, or Lunesta) or other substances that can affect sleep — including alcohol, cannabinoids, or opioids — on the nights when sleep recordings are taken at home or in the clinic.
  • People who are currently taking part in another clinical study involving an experimental treatment or medical research that is not considered compatible with this study.
  • People who regularly spend less than 5 hours in bed per night.
  • People who have consumed alcohol within at least 24 hours before a brain activity (EEG) recording, or during the clinical assessment period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 September 2026

Where this trial is recruiting

🇸🇬 Singapore

Primary endpoints

Percentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov